MPR

FDA Accepts NDA for Once-Monthly Olanzapine Injection for Schizophrenia

Using proprietary copolymer technology, TEV-’749 allows for a controlled steady release of olanzapine, a second generation antipsychotic.
Monthly Prescribing Reference

Long-Acting Subcutaneous Olanzapine Effective in Schizophrenia Trial

At the time of analysis, no cases of post injection delirium syndrome were reported. A once-monthly subcutaneous formulation of olanzapine (TEV-’749) was found to improve symptoms in patients with ...
Nasdaq

Medincell Reports Positive Phase 3 Safety Data For Olanzapine LAI; No PDSS Observed

(RTTNews) - Medincell SA (MEDCL.PA) reported that new long-term safety data from the completed Phase 3 SOLARIS trial support the potential of Olanzapine LAI (TEV-749) as the first long-acting ...

U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly ...

Detailed price information for Teva Pharmaceutical Industries ADR (TEVA-N) from The Globe and Mail including charting and trades.
Business Wire

Medincell’s partner Teva Unveils New Phase 3 Positive Results for Olanzapine LAI, and Presents Real-World Data on UZEDY

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Paris:MEDCL): TEV-‘749 / mdc-TJK - Investigational Olanzapine Long-Acting Injectable Teva presented positive data from the initial ...
Business Wire

Medincell’s Partner Teva Provides New Update on Pivotal Clinical Phase 3 of Investigational Olanzapine Long-Acting Injectable (LAI)

MONTPELLIER, France--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced during the 22 nd Annual Global Healthcare ...
Healio

Nasal olanzapine effective for reducing agitation among psychiatric patients

Please provide your email address to receive an email when new articles are posted on . “[Olanzapine intramuscular] (OLZ IM) administration requires either restraint or some level of patient ...
Investing

FDA accepts Teva’s application for monthly olanzapine injection

PARSIPPANY, N.J. and TEL AVIV - Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) and Medincell (Euronext:MEDCL) announced today that the U.S. Food and Drug Administration has accepted their ...